Recent news on Sargramostim

Favrille Reports First Quarter 2007 Financial Results  -  May 10, 2007
Genetic Engineering News (press release),This agreement helps pave the way for commercialization, including reimbursement, of FavId in combination with Berlex's Leukine(R) (sargramostim, GM-CSF),

Onmark Signs Exclusive Contracts with Pfizer and Berlex for ...  -  Apr 5, 2007
Drug Newswire (press release),...today announced that it has signed new contracts with Pfizer for Camptosar(R) (irinotecan) and with Berlex for Leukine(R) (sargramostim).

(PRN) - Jarden Reports Record Annual and Fourth Quarter 2006 ...  -  Feb 14, 2007
Bolsamania.com,...(PRN) - Favrille Announces Agreement With Berlex, Inc. Regarding Use of FavId(R) in Combination With Leukine(R) (sargramostim) in B-Cell Non-Hodgkin's

Favrille Announces Agreement With Berlex, Inc. Regarding Use of ...  -  Feb 14, 2007
PharmaLive.com (press release),Leukine(R) (sargramostim) is a recombinant granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) FDA approved for use following induction

Novel Treatment Strategy Evaluating Rituxan® plus Leukine® in ...  -  Feb 5, 2007
Cancer Consultants (press release),A clinical trial that will evaluate the effectiveness of the addition to Leukine® (sargramostim) to Rituxan® (rituximab) in patients with follicular

Favrille Reports Fourth Quarter and Year End 2006 Financial Results  -  Feb 18, 2007
Drug Newswire (press release),...(sargramostim, GM-CSF) in patients with B-cell NHL. Leukine is a. appropriate patients by enhancing immune cell function. GM-CSF has

Growth Factors May Increase Risk of AML and MDS in Post-menopausal ...  -  Feb 15, 2007
Cancer Consultants (press release),One group of patients also received growth factors Neupogen® (filgrastim) or Leukine® (sargramostim), and the other group did not receive growth factors.

Favrille Reports Fourth Quarter and Year End 2006 Financial Results  -  Feb 15, 2007
Genetic Engineering News (press release),While terms of the agreement were not disclosed, the focus is on studying the use of FavId in conjunction with Berlex's Leukine (sargramostim,

Growth Factors May Increase Risk of Secondary AML and MDS in Post ...  -  Feb 9, 2007
Cancer Consultants (press release),...cancer who receive adjuvant chemotherapy with Neupogen® (filgrastim) or Leukine® (sargramostim) may have an increased risk of developing secondary acute

Novel Treatment Strategy Evaluating Rituxan® plus Leukine® in ...  -  Dec 4, 2006
Cancer Consultants (press release),A clinical trial that will evaluate the effectiveness of the addition to Leukine® (sargramostim) to Rituxan® (rituximab) in patients with follicular

Positive Phase II Clinical Trial Results with HER2/neu Vaccine  -  Dec 15, 2006
PipelineReview.com (press release),E75 is administered as a vaccine consisting of the peptide mixed with GM-CSF (sargramostim or Leukine®) as an immunoadjuvant and administered intradermally

Current and Emerging Strategies in Biologic Therapy for IBD  -  Dec 4, 2006
Medscape (subscription)...[27] Sargramostim* is a hematopoietic factor that stimulates cells of the intestinal innate immune system. A randomized, placebo-controlled trial of

Rituxan® plus Leukine® Promising for Low-grade Lymphomas  -  Dec 11, 2006
Cancer Consultants (press release),...combination consisting of Rituxan® (rituximab) plus Leukine® (sargramostim, GM-CSF) is effective among patients with low-grade non-Hodgkin’s lymphoma,

Rituxan® and Leukine® Promising for Low-Grade Lymphomas  -  Dec 8, 2006
Cancer Consultants (press release),Dr. Jean-Francois Rossi from Montpellier, France, has reported that the combination of Rituxan (rituximab) and Leukine (Sargramostim, GM-CSF) has

Berlex Oncology Evaluating Combination Therapy for Common Form of ...  Oct 31, 2006
The trial, called PREMIER (Primary Evaluation Measuring Improved Efficacy of Rituximab with Sargramostim) is evaluating the efficacy and safety of combining ... -Earthtimes.org BY JOHN DORSCHNER  Aug 27, 2006
...per injection for anti-inflammation) and Alpha 1 proteinase inhibitor ($2,000) were routinely rejected by the computers while sargramostim injections ($500 ... -Miami Herald

Rituxan® plus Leukine® Promising for Low-grade Lymphomas  -  Dec 11, 2006
Cancer Consultants (press release),...combination consisting of Rituxan® (rituximab) plus Leukine® (sargramostim, GM-CSF) is effective among patients with low-grade non-Hodgkin’s lymphoma,

Novel Treatment Strategy Evaluating Rituxan® plus Leukine® in ...  -  Dec 4, 2006
Cancer Consultants (press release),A clinical trial that will evaluate the effectiveness of the addition to Leukine® (sargramostim) to Rituxan® (rituximab) in patients with follicular

Rituxan® and Leukine® Promising for Low-Grade Lymphomas  -  Dec 8, 2006
Cancer Consultants (press release),Dr. Jean-Francois Rossi from Montpellier, France, has reported that the combination of Rituxan (rituximab) and Leukine (Sargramostim, GM-CSF) has

Current and Emerging Strategies in Biologic Therapy for IBD  -  Dec 4, 2006
Medscape (subscription)...[27] Sargramostim* is a hematopoietic factor that stimulates cells of the intestinal innate immune system. A randomized, placebo-controlled trial of

Biological Response Modifiers in Cancer  -  Nov 15, 2006
Medscape (subscription)Hematopoietic agents such as granulocyte macrophage colony-stimulating factor (GM-CSF; sargramostim) and granulocyte colony-stimulating factor (G-CSF;



Vaccine and Antibody Treatment of Prostate Cancer  Mar 22, 2006
...fixed dose of vaccine vectors containing PSA and three human costimulatory molecules (ICAM, LFA-3 and B7.1; designated TRICOM) and sargramostim, and sequential ... - Community Dispatch

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional